Kezar struck again with second FDA hold
Kezar Life Sciences has been handed a second clinical hold by the US Food and Drug Administration (FDA) in as…
Immunology
-
-
RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull
RAPT Therapeutics has called it quits on a clinical programme evaluating zelnecirnon (RPT193) in inflammatory disorders following feedback with the…
-
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
AstraZeneca and Amgen have released topline data from a Phase III trial of its inflammatory therapy, Tezspire (tezepelumab) in patients…
-
Sepsis deaths are still high, with 50% mortality within two years
Sepsis is a life-threatening complication arising from an infection, which occurs when the body’s response to the infection damages its…
-
Priovant mulls broad autoimmune indications for brepocitinib
Priovant Therapeutics has high expectations for its lead candidate brepocitinib and plans to evaluate the therapy in multiple autoimmune indications.…
-
Gilead reports updated data from trial of acclaimed HIV PrEP drug
Gilead has presented updated data for its twice-yearly pre-exposure prophylaxis (PrEP) lenacapavir, which has shown nearly perfect efficacy in two…
-
Adicet Bio begins enrolling subjects in Phase I trial of autoimmune disease therapy
US-based biopharmaceutical company Adicet Bio has begun enrolling patients in a Phase I clinical trial of ADI-001 to treat autoimmune…
-
Union plans Phase III trial for atopic dermatitis after Phase IIb win
Union Therapeutics is looking to advance its PDE4 inhibitor, orismilast, into a Phase III clinical trial for atopic dermatitis (AD)…
-
UCB and Biogen lupus drug succeeds in Phase III, but data yet to be released
UCB and Biogen’s lupus drug has met its primary endpoint in a Phase III trial, but the companies are yet…
-
Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses
Immunovant has reported positive results from a trial investigating its monoclonal antibody drug batoclimab in Graves’ disease patients, as its…
